Financials

  • Market Capitalization 1.13 B
  • Employee 161
  • Founded 2002
  • CEO N/A
  • Website www.dbv-technologies.com
  • Headquarter France
  • FIGI BBG0076D3T39
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-18.26
ratio cours/chiffre d'affaires
474.74

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

Nouvelles